Bone and joint Infections
Use of MALDI-TOF mass spectrometry after liquid enrichment (BD Bactec™) for rapid diagnosis of bone and joint infections
24
Clinical features and outcome of bone and joint infections with streptococcal involvement: 5-year experience of interregional reference centres in the south of France
11
Two-dimentional complex modeling of bone and joint infections using agent-based simulation
199
Pharmacokinetic Variability of Daptomycin during Prolonged Therapy for Bone and Joint Infections
5
en fr Pathophysiology of bone and joint infections caused by non-aureus Staphylococcus Physiopathologie des infections ostéo-articulaires liées aux Staphylococcus non-aureus
246
View of Severe Bone and Joint Infection Management in Intensive Care Unit
9
Impact on the Gut Microbiota of Intensive and Prolonged Antimicrobial Therapy in Patients With Bone and Joint Infection
15
The Right Time to Safely Re-Evaluate Empirical Antimicrobial Treatment of Hip or Knee Prosthetic Joint Infections
10
Joint Audio Inpainting and Source Separation
9
The ENCCA‑WP7/EuroSarc/EEC/PROVABES/EURAMOS 3rd European Bone Sarcoma Networking Meeting/Joint Workshop of EU Bone Sarcoma Translational Research Networks; Vienna, Austria, September 24–25, 2015. Workshop Report
10
Biocompatibility, bone healing, and safety evaluation in rabbits with an IlluminOss bone stabilization system
24
Bone mineral: update on chemical composition and structure
10
Bisphosphonates and bone diseases: past, present and future.
6
Biotechnology, material sciences and bone repair
10
Daptomycin > 6 mg/kg/day as salvage therapy in patients with complex bone and joint infection: cohort study in a regional reference center
10
Specific effects of anorexia nervosa and obesity on bone mineral density and bone turnover in young women
14
View of Viral and fungal infections
4
View of Infections: epidemiology and prognosis
4
Enhanced human bone marrow mesenchymal stromal cell adhesion on scaffolds promotes cell survival and bone formation.
15
Autologous bone marrow cells and ischemic cardiomyopathy.
17